Structure of 25271-35-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 25271-35-6 |
Formula : | C7H14ClNO2 |
M.W : | 179.65 |
SMILES Code : | O=C(C1N(C)CCCC1)O.[H]Cl |
MDL No. : | MFCD01570459 |
InChI Key : | HENMKHNMVUDRMJ-UHFFFAOYSA-N |
Pubchem ID : | 2778261 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Num. heavy atoms | 11 |
Num. arom. heavy atoms | 0 |
Fraction Csp3 | 0.86 |
Num. rotatable bonds | 1 |
Num. H-bond acceptors | 3.0 |
Num. H-bond donors | 1.0 |
Molar Refractivity | 49.2 |
TPSA ? Topological Polar Surface Area: Calculated from |
40.54 Ų |
Log Po/w (iLOGP)? iLOGP: in-house physics-based method implemented from |
0.0 |
Log Po/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by |
-1.84 |
Log Po/w (WLOGP)? WLOGP: Atomistic method implemented from |
0.98 |
Log Po/w (MLOGP)? MLOGP: Topological method implemented from |
0.69 |
Log Po/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by |
0.31 |
Consensus Log Po/w? Consensus Log Po/w: Average of all five predictions |
0.03 |
Log S (ESOL):? ESOL: Topological method implemented from |
0.27 |
Solubility | 336.0 mg/ml ; 1.87 mol/l |
Class? Solubility class: Log S scale |
Highly soluble |
Log S (Ali)? Ali: Topological method implemented from |
1.51 |
Solubility | 5770.0 mg/ml ; 32.1 mol/l |
Class? Solubility class: Log S scale |
Highly soluble |
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by |
-0.11 |
Solubility | 139.0 mg/ml ; 0.776 mol/l |
Class? Solubility class: Log S scale |
Soluble |
GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg |
High |
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg |
Yes |
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
No |
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
No |
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
No |
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
No |
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
No |
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
No |
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from |
-8.7 cm/s |
Lipinski? Lipinski (Pfizer) filter: implemented from |
0.0 |
Ghose? Ghose filter: implemented from |
None |
Veber? Veber (GSK) filter: implemented from |
0.0 |
Egan? Egan (Pharmacia) filter: implemented from |
0.0 |
Muegge? Muegge (Bayer) filter: implemented from |
1.0 |
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat |
0.55 |
PAINS? Pan Assay Interference Structures: implemented from |
0.0 alert |
Brenk? Structural Alert: implemented from |
0.0 alert: heavy_metal |
Leadlikeness? Leadlikeness: implemented from |
No; 1 violation:MW<1.0 |
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
1.87 |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In a 3 necked flask under an atmosphere, of nitrogen, <strong>[25271-35-6]N-methylpiperidine-2-carboxylic acid hydrochloride</strong> (1.79g, 10.0 mmol), HOBt (1.35g, 10 mmol). EDC hydrochloride (1.92g, 10 mmol) and TEA (3.0Og, 30mmol) were dissolved in CH2Cl2 (100 mL, dry) at 0C. After 30 min, diphenylpropylamine (2.11g, 10 mmol) was added. After 1 more hour stirring at 0C, the mixture was allowed to stir at rt overnight. When TLC showed consumption of (nearly) all starting materials, the reaction mixture was quenched with water (150 mL). The layers were separated and the organic layer was washed with NaHCO3 (50 mL, sat.), dried (MgSO4), filtered and concentrated in vacuo to yield a yellow/orange oil (4.12g). This crude oil was purifierd by chromatography (Silica, CH2C12/CH3OH, gradient 0-3%) to yield a colorless oil (2.6g, 7.7 mmol). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Step A: A mixture of 1-methylpiperidine-2-carboxylic acid hydrochloride (0.57 g, 3.17 mmol), <strong>[17672-21-8]methyl 2-amino-3-hydroxybenzoate</strong> (0.64 g, 3.80 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.26 g, 6.34 mmol), 1-hydroxybenzotriazole (0.85 g, 6.34 mmol) and DMF (20 mL) was stirred at room temperature for 5 min, then diisopropylethylamine (1.46 mL, 8.88 mmol) was added. The resulting reaction mixture was stirred at room temperature for 17 h. The mixture was diluted with ethyl acetate (10 mL), and then washed with saturated sodium bicarbonate (10 mL). The aqueous phase was further extracted with ethyl acetate (3×40 mL). The combined organic phase was washed with brine (10 mL), dried (Na2SO4), filtered and concentrated. The crude product (a mixture of 2-amino-3-(methoxycarbonyl)phenyl 1-methylpiperidine-2-carboxylate and methyl 3-hydroxy-2-(1-methylpiperidine-2-carboxamido)benzoate) was directly elaborated in step B: MS (ESI+) m/z 293 (M+H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine; In dichloromethane; at 20℃; | A mixture of 1-methyl-6-(4-(3-(methylamino)propoxy)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]pyridine-4-carbonitrile (50mg), triethylamine (71 mul_), <strong>[25271-35-6]1-methylpiperidine-2-carboxylic acid hydrochloride</strong> (17mg), and O- benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (58mg) in DCM (1.5ml) was stirred overnight at room temperature. The mixture was washed with sodium bicarbonate and then purified by prep HPLC (acidic) to give the expected product (1 1 mg). 1H NMR (CD3OD) delta: 8.29-8.52 (m, 4H), 7.27-7.40 (m, 1 H), 4.16-4.36 (m, 2H), 4.06 (s, 3H), 3.58-3.92 (m, 2H), 2.86-3.27 (m, 5H), 2.14-2.37 (m, 6H), 1.26- 1.90 (m, 6H). MS m/z 515 (M + H). | |
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine; In dichloromethane; at 20℃; | B: N-(3-(4-(4-cyano-1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)-2-(trifluoromethyl)phenoxy)propyl)-N,1-dimethylpiperidine-2-carboxamideA mixture of 1-methyl-6-(4-(3-(methylamino)propoxy)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]pyridine-4-carbonitrile (50 mg), triethylamine (71 muL), <strong>[25271-35-6]1-methylpiperidine-2-carboxylic acid hydrochloride</strong> (17 mg), and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (58 mg) in DCM (1.5 ml) was stirred overnight at room temperature. The mixture was washed with sodium bicarbonate and then purified by prep HPLC (acidic) to give the expected product (11 mg). NMR (CD3OD) delta: 8.29-8.52 (m, 4H), 7.27-7.40 (m, 1H), 4.16-4.36 (m, 2H), 4.06 (s, 3H), 3.58-3.92 (m, 2H), 2.86-3.27 (m, 5H), 2.14-2.37 (m, 6H), 1.26-1.90 (m, 6H). MS m/z 515 (M+H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Method 26Synthesis of 5-(4-{l-r5-(l-Methyl-piperidin-2-yl)-ri,2,41oxadiazol-3-yll-cvclobutyl}- phenyl)-pyrimidin-2-ylamine (Example 281)I-2.5 R89 Ex 281To a suspension of R89 (190 mg, 1.06 mmol) in dioxane (10 ml) is added DIEA (0.18 ml, 1.06 mmol) and CDI (172 mg, 1.06 mmol) at room temperature. The mixture is stirred at 50 C for 30 minutes. After this time 1-2.5 (200 mg, 0.71 mmol) is added and the resulting mixture is heated at 100C for 20 hours. After this time the reaction is concentrated and the remaining residue is purified via column chromatography (25g silica gel, 0-5% MeOH/DCM). The product-containing fractions are combined and concentrated to give the title compound (140 mg) m/z 391.4 [M+l] |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
16% | DCM under nitrogen TEA (5.12 g, 50.6 mmol, 4.4 eq) was added to <strong>[25271-35-6]1-methylpiperidine-2-carboxylic acid hydrochloride</strong> (2.27 g, 12.65 mmol, 1.1 eq) contained in methanol (46 mL, c = 0.25) The mixture was stirred at room temperature for 30 minutes. The mixture was cooled to 0 C in an ice bath, and then ClCO2Et was slowly added dropwise over 20 minutes. To this mixture was added dropwise 3 (1.6 g, 11.5 mmol, 1.0 eq) in DCM (2 mL) and stirred overnight. The residue after rotary evaporation was purified by column chromatography to give the desired product 4 (0.5 g, 16% yield). |
A209142 [41447-18-1]
(S)-1-Methylpiperidine-2-carboxylic acid
Similarity: 0.97
A265845 [41447-17-0]
(R)-1-Methylpiperidine-2-carboxylic acid
Similarity: 0.97
A130065 [15862-86-9]
Piperidine-2-carboxylic acid hydrochloride
Similarity: 0.95
A344377 [2133-33-7]
(S)-Piperidine-2-carboxylic acid hydrochloride
Similarity: 0.95
A226021 [99571-58-1]
6-Methylpiperidine-2-carboxylic acid
Similarity: 0.92
A209142 [41447-18-1]
(S)-1-Methylpiperidine-2-carboxylic acid
Similarity: 0.97
A265845 [41447-17-0]
(R)-1-Methylpiperidine-2-carboxylic acid
Similarity: 0.97
A130065 [15862-86-9]
Piperidine-2-carboxylic acid hydrochloride
Similarity: 0.95
A344377 [2133-33-7]
(S)-Piperidine-2-carboxylic acid hydrochloride
Similarity: 0.95
A226021 [99571-58-1]
6-Methylpiperidine-2-carboxylic acid
Similarity: 0.92